Page 279 - Haematologica - Vol. 105 n. 6 - June 2020

90Y-Anti-CD45 Antibody for Leukemia/Myelodysplasia
References
1. Kahl C, Storer BE, Sandmaier BM, et al. Relapse risk among patients with malig- nant diseases given allogeneic hematopoi- etic cell transplantation after nonmyeloab- lative conditioning. Blood. 2007;110(7):2744-2748.
2. Pagel JM, Gooley TA, Rajendran J, et al. Allogeneic hematopoietic cell transplanta- tion after conditioning with 131I-anti- CD45 antibody plus fludarabine and low- dose total body irradiation for elderly patients with advanced acute myeloid leukemia or high-risk myelodysplastic syn- drome. Blood. 2009;114(27):5444-5453.
3. Araki D, Wood BL, Othus M, et al. Allogeneic hematopoietic cell transplanta- tion for acute myeloid leukemia: Time to move toward a minimal residual disease- based definition of complete remission? J Clin Oncol. 2016;34(4):329-336.
4. O'Donoghue JA. Optimal therapeutic strategies for radioimmunotherapy. Recent Results Cancer Res. 1996;141:77-99.
5. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malig- nancies: replacing high-dose cytotoxic ther- apy with graft-versus-tumor effects. Blood. 2001;97(11):3390-3400.
6. Bearman SI, Appelbaum FR, Buckner CD, et al. Regimen-related toxicity in patients undergoing bone marrow transplantation. J Clin Oncol. 1988;6(10):1562-1568.
7. StorerBE.Small-sampleconfidencesetsfor the MTD in a phase I clinical trial. Biometrics. 1993;49(4):1117-1125.
8. SlovakML,KopeckyKJ,CassilethPA,etal. Karyotypic analysis predicts outcome of
preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group study. Blood. 2000;96(13):4075-4083.
9. Sierra J, Storer B, Hansen JA, et al. Transplantation of marrow cells from unre- lated donors for treatment of high-risk acute leukemia: the effect of leukemic bur- den, donor HLA-matching, and marrow cell dose. Blood. 1997;89(11):4226-4235.
10. Miller CB, Zehnbauer BA, Piantadosi S, Rowley SD, Jones RJ. Correlation of occult clonogenic leukemia drug sensitivity with relapse after autologous bone marrow transplantation. Blood. 1991;78(4):1125- 1131.
11. Clift RA, Buckner CD, Appelbaum FR, et al. Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: A randomized trial of two irradiation regimens. Blood. 1990;76(9):1867-1871.
12. Laport GG, Sandmaier BM, Storer BE, et al. Reduced-intensity conditioning followed by allogeneic hematopoietic cell transplan- tation for adult patients with myelodys- plastic syndrome and myeloproliferative disorders. Biol Blood Marrow Transplant. 2008;14(2):246-255.
13. Sorror ML, Storer BE, Sandmaier BM, et al. Five-year follow-up of patients with advanced chronic lymphocytic leukemia treated with allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning. J Clin Oncol. 2008;26(30):4912-4920.
14. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoiet- ic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol.
2010;28(17):2859-2867.
15. Mawad R, Gooley TA, Rajendran JG, et al.
Radiolabeled anti-CD45 antibody with reduced-intensity conditioning and allo- geneic transplantation for younger patients with advanced acute myeloid leukemia or myelodysplastic syndrome. Biol Blood Marrow Transplant. 2014;20(9):1363-1368.
16. Walter RB, Gyurkocza B, Storer BE, et al. Comparison of minimal residual disease as outcome predictor for AML patients in first complete remission undergoing myeloabla- tive or nonmyeloablative allogeneic hematopoietic cell transplantation. Leukemia. 2015;29(1):137-144.
17. Mielcarek M, Burroughs L, Leisenring W, et al. Prognostic relevance of early-onset graft-versus-host disease following non- myeloablative hematopoietic cell trans- plantation. Br J Haematol. 2005;129(3):381- 391.
18. Wong R, Giralt SA, Martin T, et al. Reduced-intensity conditioning for unrelat- ed donor hematopoietic stem cell trans- plantation as treatment for myeloid malig- nancies in patients older than 55 years. Blood. 2003;102(8):3052-3059.
19. Kroger N, Bornhauser M, Ehninger G, et al. Allogeneic stem cell transplantation after a fludarabine/busulfan-based reduced-inten- sity conditioning in patients with myelodysplastic syndrome or secondary acute myeloid leukemia. Ann Hematol. 2003;82(6):336-342.
20. Salako QA, O'Donnell RT, DeNardo SJ. Effects of radiolysis on yttrium-90-labeled Lym-1 antibody preparations. J Nucl Med. 1998;39(4):667-670.
21. Hall EJ, Giaccia AJ. Radiobiology for the radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins, 2006.
haematologica | 2020; 105(6)
1737